Farmas USA

Puede, puede.... deja no tientes a la bestia.

dvax

joder que entrada hice, pero a veces los stop te ayudan y otras te pierdes cosas, aunque los prefiero.

Nos hacemos viejos.

TOCA

Esta me la ha descubierto hoy Hartman y se me hace interesante. Salió a bolsa en abril a 10 $. TOCA seguro :D (chiste malo).

Tocagen has treated 126 brain cancer patients in three Phase 1 clinical trials. The company had also started the Phase 2 portion of a planned Phase 2/3 trial. According to Tocagen’s prospectus, enrollment of that 187 patient Phase 2 trial was completed in February. Tocagen says in the filing that it plans to use $25 million of the IPO proceeds to finance the rest of the Phase 2 trial through a review of top line results. Tocagen plans to use $20 million for drug manufacturing; another $15 million is earmarked for planned Phase 1b clinical trials in patients newly diagnosed with high-grade glioma.

http://www.xconomy.com/san-diego/2017/04/13/tocagen-ipo-raises-85m-to-test-gene-therapy-in-brain-cancer-trials/

whose platform rests on the use of replicating retroviral vectors to deliver specific genes to tumor cells. Their most advanced drug candidate, Toca511, forces the tumors to express an enzyme called cysteine deaminase, which is not natively found in humans.

The follow on is the administration of Toca FC, which the body doesn't normally do anything with. However, when Toca FC is encountered by cysteine deaminase, it is converted into 5-fluororacil, a potent chemotherapeutic agent. What's more, once a cancer cell dies, it spills out the 5-fluorouracil to nearby tumors, in a strategy reminiscent of the antibody-drug conjugates like T-DM1.

Toca511 and Toca FC are currently being investigated in a late-stage study for patients with recurrent, high-grade glioma, which would include glioblastoma. This trial is fully enrolled, with results expected in the first half of 2018.

TOCA was recently granted PRIME designation

DVAX. La tengo muy monitorizada , no termina de sobrepasar los 10,50 con solvencia y lo mismo se gira y empieza a caer como una condenada a 4,50...si vuelve a caer a 8, es una firme candidata a volver a entrar...ya que da mucho juego el rango 7,5/10,5.

😉

DEPO

Tiene pinta de que quieren darle un empujón antes de resultados... Yo me saldré antes.

HZNP semanal

hoy he picoteado esta pajara ... con vistas a que quiera cerrar la semana arriba ... ya veremos ... 

De esas cosas que costarían de explicar a un profano: baja ingresos un 8%, resultados un 12%... y las acciones suben un 3%.

Gilead Sciences Q2 top line down 8%; earnings down 12%; guidance raised; shares up 3% after hours on consensus beat

https://seekingalpha.com/news/3281692-gilead-sciences-q2-top-line-8-percent-earnings-12-percent-guidance-raised-shares-3-percent

GILD